CoChat
Sign Up
Cited by 15Rheumatoid Arthritis Research and TherapiesImmune cells in cancerNatural Compounds in Disease Treatment

Inhibition of lipid phosphatase SHIP1 expands myeloid-derived suppressor cells and attenuates rheumatoid arthritis in mice

Open access
So, Eui-Young, Sun, Changqi, Wu, Keith Q., Dubielecka, Patrycja M., Reginato, Anthony M., Liang, Olin D.·2021·American Journal of Physiology-Cell Physiology
DOI 10.1152/ajpcell.00433.2020PMC PMC8461811
Open this paper in CoChat — free account

Abstract

Rheumatoid arthritis (RA) is a debilitating autoimmune disease of unknown cause, characterized by infiltration and accumulation of activated immune cells in the synovial joints where cartilage and bone destructions occur. Myeloid-derived suppressor cells (MDSCs) are of myeloid origin and are able to suppress T cell responses. Src homology 2 domain-containing inositol polyphosphate 5-phosphatase 1 (SHIP1) was shown to be involved in the regulation of MDSC differentiation. The purpose of the present study was to investigate the effect of inhibition of SHIP1 on the expansion of MDSCs in RA using a collagen-induced inflammatory arthritis (CIA) mouse model. In DBA/1 mice, treatment with a small molecule-specific SHIP1 inhibitor 3α-aminocholestane (3AC) induced a marked expansion of MDSCs in vivo. Both pretreatment with 3AC of DBA/1 mice prior to CIA induction and intervention with 3AC during CIA progression significantly reduced disease incidence and severity. Adoptive transfer of MDSCs isolated from 3AC-treated mice, but not naïve MDSCs from normal mice, into CIA mice significantly reduced disease incidence and severity, indicating that the 3AC-induced MDSCs were the cellular mediators of the observed amelioration of the disease. In conclusion, inhibition of SHIP1 expands MDSCs in vivo and attenuates development of CIA in mice. Small molecule-specific inhibition of SHIP1 may therefore offer therapeutic benefit to patients with RA and other autoimmune diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1152/ajpcell.00433.2020

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • 3-alpha-Aminocholestane (3AC) is a selective inhibitor of INPP5D.

    “Here, we used 3-alpha-Aminocholestane (3AC), a compound previously reported to be a selective inhibitor of INPP5D39, which has been utilized in several studies to reduce INPP5D activity in vivo in mice and in vitro cell culture39–47.”

    From INPP5D regulates inflammasome activation in human microglia (2023) · cites this paper as [47]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. [1]Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 39: 222–228, 2012. doi: 10.1016/j.jaut.2012.05.021. [DOI] [PubMed] [Google Scholar] · DOI
  2. [2]Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 373: 659–672, 2009. doi: 10.1016/S0140-6736(09)60008-8. [DOI] [PubMed] [Google Scholar] · DOI
  3. [3]Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 4: 605–614, 2008. doi: 10.2147/vhrm.s2453. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  4. [4]Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 181: 787–96, 2009[Erratum inCMAJ182: 806, 2018]. doi: 10.1503/cmaj.091391. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  5. [5]Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 11Suppl 1: S1, 2009. doi: 10.1186/ar2666. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  6. [6]Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24: 302–306, 2003. doi: 10.1016/s1471-4906(03)00132-7. [DOI] [PubMed] [Google Scholar] · DOI
  7. [7]Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 74: 186–196, 2003. doi: 10.1189/jlb.0103010. [DOI] [PubMed] [Google Scholar] · DOI
  8. [8]Dilek N, Vuillefroy de Silly R, Blancho G, Vanhove B. Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. Front Immunol 3: 208, 2012. doi: 10.3389/fimmu.2012.00208. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  9. [9]Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162–174, 2009. doi: 10.1038/nri2506. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  10. [10]Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 12: 417–430, 2012. doi: 10.1038/nri3227. [DOI] [PubMed] [Google Scholar] · DOI
  11. [11]Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, Mastorodemos V, Plaitakis A, Sharpe A, Boumpas D, Verginis P. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol 188: 1136–1146, 2012[Erratum inJ Immunol192: 1334, 2014]. doi: 10.4049/jimmunol.1101816. [DOI] [PubMed] [Google Scholar] · DOI
  12. [12]Jiao Z, Hua S, Wang W, Wang H, Gao J, Wang X. Increased circulating myeloid-derived suppressor cells correlated negatively with Th17 cells in patients with rheumatoid arthritis. Scand J Rheumatol 42: 85–90, 2013. doi: 10.3109/03009742.2012.716450. [DOI] [PubMed] [Google Scholar] · DOI
  13. [13]Kurko J, Vida A, Glant TT, Scanzello CR, Katz RS, Nair A, Szekanecz Z, Mikecz K. Identification of myeloid-derived suppressor cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet Disord 15: 281, 2014. doi: 10.1186/1471-2474-15-281. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  14. [14]Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791–5802, 2008. doi: 10.4049/jimmunol.181.8.5791. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  15. [15]Fujii W, Ashihara E, Hirai H, Nagahara H, Kajitani N, Fujioka K, Murakami K, Seno T, Yamamoto A, Ishino H, Kohno M, Maekawa T, Kawahito Y. Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J Immunol 191: 1073–1081, 2013. doi: 10.4049/jimmunol.1203535. [DOI] [PubMed] [Google Scholar] · DOI
  16. [16]OduroKA, Jr., Liu F, Tan Q, Kim CK, Lubman O, Fremont D, Mills JC, Choi K. Myeloid skewing in murine autoimmune arthritis occurs in hematopoietic stem and primitive progenitor cells. Blood 120: 2203–2213, 2012. doi: 10.1182/blood-2011-11-391342. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  17. [17]Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275: 665–668, 1997. doi: 10.1126/science.275.5300.665. [DOI] [PubMed] [Google Scholar] · DOI
  18. [19]Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13: 283–296, 2012. doi: 10.1038/nrm3330. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  19. [20]Fernandes S, Iyer S, Kerr WG. Role of SHIP1 in cancer and mucosal inflammation. Ann N Y Acad Sci 1280: 6–10, 2013. doi: 10.1111/nyas.12038. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  20. [21]Ma K, Cheung SM, Marshall AJ, Duronio V. PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity. Cell Signal 20: 684–694, 2008. doi: 10.1016/j.cellsig.2007.12.004. [DOI] [PubMed] [Google Scholar] · DOI
  21. [22]Scheid MP, Huber M, Damen JE, Hughes M, Kang V, Neilsen P, Prestwich GD, Krystal G, Duronio V. Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3,4)P2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J Biol Chem 277: 9027–9035, 2002. doi: 10.1074/jbc.M106755200. [DOI] [PubMed] [Google Scholar] · DOI
  22. [23]Collazo MM, Paraiso KH, Park MY, Hazen AL, Kerr WG. Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP. Eur J Immunol 42: 1785–1795, 2012. doi: 10.1002/eji.201142092. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  23. [24]Ghansah T, Paraiso KH, Highfill S, Desponts C, May S, McIntosh JK, Wang JW, Ninos J, Brayer J, Cheng F, Sotomayor E, Kerr WG. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol 173: 7324–7330, 2004. doi: 10.4049/jimmunol.173.12.7324. [DOI] [PubMed] [Google Scholar] · DOI
  24. [25]Paraiso KH, Ghansah T, Costello A, Engelman RW, Kerr WG. Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease. J Immunol 178: 2893–2900, 2007. doi: 10.4049/jimmunol.178.5.2893. [DOI] [PubMed] [Google Scholar] · DOI
  25. [26]Locke NR, Patterson SJ, Hamilton MJ, Sly LM, Krystal G, Levings MK. SHIP regulates the reciprocal development of T regulatory and Th17 cells. J Immunol 183: 975–983, 2009. doi: 10.4049/jimmunol.0803749. [DOI] [PubMed] [Google Scholar] · DOI
  26. [28]Antignano F, Ibaraki M, Kim C, Ruschmann J, Zhang A, Helgason CD, Krystal G. SHIP is required for dendritic cell maturation. J Immunol 184: 2805–2813, 2010. doi: 10.4049/jimmunol.0903170. [DOI] [PubMed] [Google Scholar] · DOI
  27. [29]So EY, Sun C, Reginato AM, Dubielecka PM, Ouchi T, Liang OD. Loss of lipid phosphatase SHIP1 promotes macrophage differentiation through suppression of dendritic cell differentiation. Cancer Biol Ther 20: 201–211, 2019. doi: 10.1080/15384047.2018.1523846. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  28. [30]Campbell IK, Hamilton JA, Wicks IP. Collagen-induced arthritis in C57BL/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis. Eur J Immunol 30: 1568–1575, 2000. doi: 10.1002/1521-4141(200006)30:6<1568::AID-IMMU1568>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar] · DOI
  29. [31]Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151–1164, 1995. [PubMed] [Google Scholar]
  30. [32]Fujimura T, Kambayashi Y, Aiba S. Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology 1: 1433–1434, 2012. doi: 10.4161/onci.21176. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  31. [33]Collazo MM, Wood D, Paraiso KH, Lund E, Engelman RW, Le CT, Stauch D, Kotsch K, Kerr WG. SHIP limits immunoregulatory capacity in the T-cell compartment. Blood 113: 2934–2944, 2009. doi: 10.1182/blood-2008-09-181164. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  32. [34]Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30: 576–587, 2009. doi: 10.1016/j.immuni.2009.02.007. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  33. [35]Harrison OJ, Srinivasan N, Pott J, Schiering C, Krausgruber T, Ilott NE, Maloy KJ. Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3(+) Treg cell function in the intestine. Mucosal Immunol 8: 1226–1236, 2015. doi: 10.1038/mi.2015.13. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  34. [36]van Lent PL, Grevers L, Lubberts E, de Vries TJ, Nabbe KC, Verbeek S, Oppers B, Sloetjes A, Blom AB, van den Berg WB. Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation. Arthritis Rheum 54: 3868–3877, 2006. doi: 10.1002/art.22253. [DOI] [PubMed] [Google Scholar] · DOI
  35. [37]Crook KR, Jin M, Weeks MF, Rampersad RR, Baldi RM, Glekas AS, Shen Y, Esserman DA, Little P, Schwartz TA, Liu P. Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. J Leukoc Biol 97: 573–582, 2015. doi: 10.1189/jlb.4A0314-139R. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  36. [38]Bessis N, Decker P, Assier E, Semerano L, Boissier MC. Arthritis models: usefulness and interpretation. Semin Immunopathol 39: 469–486, 2017. doi: 10.1007/s00281-017-0622-4. [DOI] [PubMed] [Google Scholar] · DOI
  37. [39]Fuhler GM, Brooks R, Toms B, Iyer S, Gengo EA, Park MY, Gumbleton M, Viernes DR, Chisholm JD, Kerr WG. Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med 18: 65–75, 2012. doi: 10.2119/molmed.2011.00178. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  38. [40]Gumbleton M, Sudan R, Fernandes S, Engelman RW, Russo CM, Chisholm JD, Kerr WG. Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival. Sci Signal 10: eaam5353, 2017. doi: 10.1126/scisignal.aam5353. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  39. [41]Srivastava N, Iyer S, Sudan R, Youngs C, Engelman RW, Howard KT, Russo CM, Chisholm JD, Kerr WG. A small-molecule inhibitor of SHIP1 reverses age- and diet-associated obesity and metabolic syndrome. JCI Insight 1: e88544, 2016. doi: 10.1172/jci.insight.88544. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  40. [42]Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123–1131, 2006. doi: 10.1158/0008-5472.CAN-05-1299. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  41. [43]Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, Divino CM, Chen SH. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 70: 99–108, 2010. doi: 10.1158/0008-5472.CAN-09-1882. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  42. [44]Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68: 5439–5449, 2008. doi: 10.1158/0008-5472.CAN-07-6621. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  43. [45]Parry RV, Harris SJ, Ward SG. Fine tuning T lymphocytes: a role for the lipid phosphatase SHIP-1. Biochim Biophys Acta 1804: 592–597, 2010. doi: 10.1016/j.bbapap.2009.09.019. [DOI] [PubMed] [Google Scholar] · DOI
  44. [46]Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, Chappel SM, Borowski A, Jirik F, Krystal G, Humphries RK. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 12: 1610–1620, 1998. doi: 10.1101/gad.12.11.1610. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  45. [47]Dong S, Corre B, Foulon E, Dufour E, Veillette A, Acuto O, Michel F. T cell receptor for antigen induces linker for activation of T cell-dependent activation of a negative signaling complex involving Dok-2, SHIP-1, and Grb-2. J Exp Med 203: 2509–2518, 2006. doi: 10.1084/jem.20060650. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  46. [48]Tarasenko T, Kole HK, Chi AW, Mentink-Kane MM, Wynn TA, Bolland S. T cell-specific deletion of the inositol phosphatase SHIP reveals its role in regulating Th1/Th2 and cytotoxic responses. Proc Natl Acad Sci USA 104: 11382–11387, 2007. doi: 10.1073/pnas.0704853104. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  47. [49]Waterman PM, Marschner S, Brandl E, Cambier JC. The inositol 5-phosphatase SHIP-1 and adaptors Dok-1 and 2 play central roles in CD4-mediated inhibitory signaling. Immunol Lett 143: 122–130, 2012. doi: 10.1016/j.imlet.2012.02.009. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  48. [50]Park MY, Srivastava N, Sudan R, Viernes DR, Chisholm JD, Engelman RW, Kerr WG. Impaired T-cell survival promotes mucosal inflammatory disease in SHIP1-deficient mice. Mucosal Immunol 7: 1429–1439, 2014. doi: 10.1038/mi.2014.32. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  49. [51]Gumbleton M, Vivier E, Kerr WG. SHIP1 intrinsically regulates NK cell signaling and education, resulting in tolerance of an MHC class I-mismatched bone marrow graft in mice. J Immunol 194: 2847–2854, 2015. doi: 10.4049/jimmunol.1402930. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  50. [52]Kurowska-Stolarska M, Alivernini S, Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, Reilly J, Ierna M, Fraser AR, Stolarski B, McSharry C, Hueber AJ, Baxter D, Hunter J, Gay S, Liew FY, McInnes IB. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA 108: 11193–11198, 2011. doi: 10.1073/pnas.1019536108. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  51. [53]O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 106: 7113–7118, 2009. doi: 10.1073/pnas.0902636106. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  52. [54]Li L, Zhang J, Diao W, Wang D, Wei Y, Zhang CY, Zen K. MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol 192: 1034–1043, 2014. doi: 10.4049/jimmunol.1301309. [DOI] [PubMed] [Google Scholar] · DOI
  53. [55]Zhou P, Kitaura H, Teitelbaum SL, Krystal G, Ross FP, Takeshita S. SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27. J Immunol 177: 8777–8784, 2006. doi: 10.4049/jimmunol.177.12.8777. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  54. [56]Asquith DL, Miller AM, McInnes IB, Liew FY. Animal models of rheumatoid arthritis. Eur J Immunol 39: 2040–2044, 2009. doi: 10.1002/eji.200939578. [DOI] [PubMed] [Google Scholar] · DOI
  55. [57]Rieber N, Gille C, Kostlin N, Schafer I, Spring B, Ost M, Spieles H, Kugel HA, Pfeiffer M, Heininger V, Alkhaled M, Hector A, Mays L, Kormann M, Zundel S, Fuchs J, Handgretinger R, Poets CF, Hartl D. Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive immune responses. Clin Exp Immunol 174: 45–52, 2013. doi: 10.1111/cei.12143. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  56. [58]Rieber N, Brand A, Hector A, Graepler-Mainka U, Ost M, Schafer I, Wecker I, Neri D, Wirth A, Mays L, Zundel S, Fuchs J, Handgretinger R, Stern M, Hogardt M, Doring G, Riethmuller J, Kormann M, Hartl D. Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease. J Immunol 190: 1276–1284, 2013. doi: 10.4049/jimmunol.1202144. [DOI] [PubMed] [Google Scholar] · DOI
  57. [59]Rieber N, Wecker I, Neri D, Fuchs K, Schafer I, Brand A, Pfeiffer M, Lang P, Bethge W, Amon O, Handgretinger R, Hartl D. Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD. Bone Marrow Transplant 49: 545–552, 2014. doi: 10.1038/bmt.2013.236. [DOI] [PubMed] [Google Scholar] · DOI
  58. [60]Yi H, Guo C, Yu X, Zuo D, Wang XY. Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis. J Immunol 189: 4295–4304, 2012. doi: 10.4049/jimmunol.1200086. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  59. [61]Guo C, Hu F, Yi H, Feng Z, Li C, Shi L, Li Y, Liu H, Yu X, Wang H, Li J, Li Z, Wang XY. Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann Rheum Dis 75: 278–285, 2016. doi: 10.1136/annrheumdis-2014-205508. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  60. [62]Zhang H, Wang S, Huang Y, Wang H, Zhao J, Gaskin F, Yang N, Fu SM. Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation. Clin Immunol 157: 175–186, 2015. doi: 10.1016/j.clim.2015.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  61. [63]Pedicone C, Meyer ST, Chisholm JD, Kerr WG. Targeting SHIP1 and SHIP2 in Cancer. Cancers (Basel) 13: 890, 2021. doi: 10.3390/cancers13040890. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  62. [64]Wang Y, Tian J, Wang S. The potential therapeutic role of myeloid-derived suppressor cells in autoimmune arthritis. Semin Arthritis Rheum 45: 490–495, 2016. doi: 10.1016/j.semarthrit.2015.07.003. [DOI] [PubMed] [Google Scholar] · DOI
  63. [65]Wen L, Gong P, Liang C, Shou D, Liu B, Chen Y, Bao C, Chen L, Liu X, Liang T, Gong W. Interplay between myeloid-derived suppressor cells (MDSCs) and Th17 cells: foe or friend? Oncotarget 7: 35490–35496, 2016. doi: 10.18632/oncotarget.8204. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI

Cited by

Sorted by citations

Authors
So, E.-Y., Sun, C., Wu, K. Q., Dubielecka, P. M., Reginato, A. M., & Liang, O. D.
Affiliations
Brown University (US)
Corresponding author
Liang, Olin D.
ORCID
Venue
American Journal of Physiology-Cell Physiology
Publisher
American Physiological Society
Published
2021-09-01
Volume
321
Issue
3
Pages
C569-C584
ISSN
  • 0363-6143 (ISSN-L)
  • 1522-1563
DOI
10.1152/ajpcell.00433.2020
PMC
PMC8461811
OpenAlex
W3184101272
Cited by
15
References
2
Citations by year
2026: 2 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 4
FWCI
1.69
Type
journal article
Language
en
Open access
Locations
  • American Journal of Physiology-Cell Physiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Heart Association (18TPA34110329)
  • HHS | NIH | National Heart, Lung, and Blood Institute (R01 HL112860, T32 HL116249)
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK112808)
  • HHS | NIH | National Institute of General Medical Sciences (P20 GM119943, P20 GM103652, P30 GM122732)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
rheumatoid arthritis, myeloid-derived suppressor cells, SHIP1, collagen-induced arthritis, autoimmune disease, adoptive transfer, T cell suppression, synovitis, DBA/1 mice
MeSH terms
Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases, Myeloid-Derived Suppressor Cells, Animals, Anti-Inflammatory Agents, Arthritis, Experimental, Arthritis, Rheumatoid, Cell Communication, Cell Differentiation, Cholestanes, Humans, Mice, Inbred DBA, Severity of Illness Index, Gene Expression, Joint Capsule, Mice, Knockout, Adoptive Transfer, Cell Proliferation, T-Lymphocytes, Regulatory, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review